JP2016501875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501875A5 JP2016501875A5 JP2015545419A JP2015545419A JP2016501875A5 JP 2016501875 A5 JP2016501875 A5 JP 2016501875A5 JP 2015545419 A JP2015545419 A JP 2015545419A JP 2015545419 A JP2015545419 A JP 2015545419A JP 2016501875 A5 JP2016501875 A5 JP 2016501875A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- residue
- nos
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 101800004937 Protein C Proteins 0.000 claims 3
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 3
- 101800001700 Saposin-D Proteins 0.000 claims 3
- 229960000856 protein c Drugs 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 230000003024 amidolytic effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731368P | 2012-11-29 | 2012-11-29 | |
| US61/731,368 | 2012-11-29 | ||
| PCT/US2013/072137 WO2014085527A1 (en) | 2012-11-29 | 2013-11-27 | Humanized monoclonal antibodies against activated protein c and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501875A JP2016501875A (ja) | 2016-01-21 |
| JP2016501875A5 true JP2016501875A5 (enExample) | 2017-01-12 |
Family
ID=50828440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545419A Pending JP2016501875A (ja) | 2012-11-29 | 2013-11-27 | 活性化プロテインｃに対するヒト化モノクローナル抗体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9657111B2 (enExample) |
| EP (1) | EP2925360A4 (enExample) |
| JP (1) | JP2016501875A (enExample) |
| KR (1) | KR20150088853A (enExample) |
| CN (1) | CN104936618A (enExample) |
| AR (1) | AR093672A1 (enExample) |
| AU (1) | AU2013352260A1 (enExample) |
| BR (1) | BR112015012458A2 (enExample) |
| CA (1) | CA2892748A1 (enExample) |
| HK (1) | HK1215174A1 (enExample) |
| IL (1) | IL238920A0 (enExample) |
| MX (1) | MX2015006738A (enExample) |
| RU (1) | RU2015125343A (enExample) |
| SG (1) | SG11201504035PA (enExample) |
| TW (1) | TW201437229A (enExample) |
| UY (1) | UY35160A (enExample) |
| WO (1) | WO2014085527A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179435A1 (en) * | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| WO2017087391A1 (en) * | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| US12319744B2 (en) | 2018-09-06 | 2025-06-03 | Board Of Regents, The University Of Texas System | Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR) |
| CN115611986B (zh) * | 2021-07-13 | 2025-08-12 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202253A (en) | 1988-12-30 | 1993-04-13 | Oklahoma Medical Research Foundation | Monoclonal antibody specific for protein C and antibody purification method |
| US7247453B1 (en) | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
| US5279956A (en) * | 1991-06-24 | 1994-01-18 | The Scripps Research Institute | Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C |
| US5695993A (en) | 1994-08-12 | 1997-12-09 | Oklahoma Medical Research Foundation | Cloning and regulation of an endothelial cell protein C/activated protein C receptor |
| DE69735421T2 (de) | 1996-04-24 | 2006-10-19 | The Regents Of The University Of Michigan, Ann Arbor | Gegen inaktivierung resistenter faktor viii |
| US6953568B1 (en) | 1998-08-25 | 2005-10-11 | Oklahoma Medical Research Foundation | Targeting of molecules to large vessel endothelium using EPCR |
| US6989241B2 (en) | 2000-10-02 | 2006-01-24 | Oklahoma Medical Research Foundation | Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor |
| US20030203355A1 (en) | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| TW200407335A (en) * | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| JP4829609B2 (ja) * | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| AU2006330411B2 (en) * | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| US7846443B2 (en) | 2006-08-11 | 2010-12-07 | Schering Corporation | Antibodies to IL-17A |
| US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| WO2009055669A2 (en) * | 2007-10-26 | 2009-04-30 | Oklahoma Medical Research Foundation | Monoclonal antibodies against activated and unactivated protein c |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| GB201011771D0 (en) | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
-
2013
- 2013-11-27 JP JP2015545419A patent/JP2016501875A/ja active Pending
- 2013-11-27 SG SG11201504035PA patent/SG11201504035PA/en unknown
- 2013-11-27 RU RU2015125343A patent/RU2015125343A/ru not_active Application Discontinuation
- 2013-11-27 CA CA2892748A patent/CA2892748A1/en not_active Abandoned
- 2013-11-27 HK HK16103170.8A patent/HK1215174A1/zh unknown
- 2013-11-27 AU AU2013352260A patent/AU2013352260A1/en not_active Abandoned
- 2013-11-27 BR BR112015012458A patent/BR112015012458A2/pt not_active Application Discontinuation
- 2013-11-27 US US14/443,696 patent/US9657111B2/en not_active Ceased
- 2013-11-27 EP EP13857737.4A patent/EP2925360A4/en not_active Ceased
- 2013-11-27 MX MX2015006738A patent/MX2015006738A/es unknown
- 2013-11-27 CN CN201380071700.3A patent/CN104936618A/zh active Pending
- 2013-11-27 KR KR1020157016868A patent/KR20150088853A/ko not_active Withdrawn
- 2013-11-27 WO PCT/US2013/072137 patent/WO2014085527A1/en not_active Ceased
- 2013-11-27 US US16/419,319 patent/USRE49099E1/en active Active
- 2013-11-29 UY UY0001035160A patent/UY35160A/es unknown
- 2013-11-29 TW TW102143763A patent/TW201437229A/zh unknown
- 2013-11-29 AR ARP130104418A patent/AR093672A1/es unknown
-
2015
- 2015-05-20 IL IL238920A patent/IL238920A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263669A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| JP2017113019A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| RU2014143639A (ru) | Регулируемые протеазой антитела | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| EA201991704A2 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| PH12018500640A1 (en) | Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi) | |
| JP2014205674A5 (enExample) | ||
| EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| EP2582722A4 (en) | ANTIBODIES AGAINST GD2 | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| JP2010202664A5 (enExample) | ||
| EA201301173A1 (ru) | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| Shen et al. | Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities | |
| UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
| JP2016501875A5 (enExample) | ||
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| MX388251B (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. |